Key Facts

- President Donald J. Trump signed an Executive Order on 29 September 2026 to eliminate invasive ticks and mosquitoes on federal lands in Washington, D.C. [1]

- The Order directs the Secretaries of the Interior, Agriculture, Health and Human Services, and the Administrators of the Environmental Protection Agency and General Services to reduce mosquito populations by 90 % and tick populations by 50 % in the District by 2028 using non‑chemical, technology‑enabled methods [1]

- Agencies are instructed to develop a regulatory framework for the development and release of advanced tick and mosquito control technologies and to submit that framework for review [1]

- The Order expands the existing Lyme Disease Moonshot initiative with prize competitions and additional research and development programs to prevent and treat tick‑ and mosquito‑borne diseases [1]

- The Order tasks the USDA and HHS to explore labeling options for food and drug products that contain significant amounts of alpha‑galactose, similar to other allergy warnings [1]

Executive Order Targets D.C. Vector Threats

The September 29, 2026 fact sheet announces that President Trump exercised his constitutional authority to issue an Executive Order aimed at invasive disease‑carrying pests within the capital’s federal jurisdiction. The document identifies foreign invasive mosquitoes—specifically Asian tiger and Egyptian species—as dominant in some parts of Washington, D.C., and links their spread to heightened public‑health risk. It also notes expanding tick populations as a source of debilitating illnesses for Americans, their pets, and livestock, underscoring the urgency of a coordinated federal response.

By limiting the scope to the federal jurisdiction of Washington, D.C., the Order creates a geographically bounded pilot model that the administration says can later be scaled nationwide. The Order repeatedly emphasizes “safe and effective, non‑chemical, and technology‑enabled methods” as the preferred approach, describing these methods as non‑chemical alternatives to traditional pesticide regimes. The language signals that the campaign will focus on properties directly controlled by the government rather than private land, aligning with the administration’s broader narrative of protecting public health while preserving outdoor recreation.

In addition to the pest‑reduction goals, the Order references Alpha‑gal syndrome—a red‑meat allergy triggered by tick bites—as an emerging health concern tied to the spread of ticks. By linking the pest‑control effort to this specific medical condition, the fact sheet expands the policy’s rationale beyond vector control to encompass broader consumer‑health protections, including potential labeling requirements for products containing alpha‑galactose.

Mechanics and Agency Responsibilities

The Order delineates a multi‑agency task force that includes the Secretaries of the Interior, Agriculture, and Health and Human Services, as well as the Administrators of the Environmental Protection Agency and General Services. Each entity receives explicit directives:

- **Interior and Agriculture**: Oversee habitat remediation on federal lands and coordinate with other agencies to identify breeding sites.

- **EPA**: In concert with Agriculture and HHS, craft a regulatory framework that sets standards for the development and release of advanced, safe, and effective tick and mosquito control technologies.

- **HHS**: Build on the existing Lyme Disease Moonshot initiative, launching prize competitions and additional research programs aimed at preventing and treating tick‑ and mosquito‑borne diseases.

- **USDA and HHS**: Explore labeling options for food and drug products that contain significant alpha‑galactose.

The regulatory‑framework component obligates the EPA, Agriculture, and HHS to outline standards for novel control technologies. The fact sheet does not specify a filing deadline, but the language “to submit a regulatory framework” implies an actionable deliverable that agencies must produce before broader deployment can proceed. The record does not address the specific technologies that may be used, such as gene‑drive mosquitoes or automated trap systems.

Prize competitions and research programs are another core mechanism. The Order directs HHS to expand the Lyme Disease Moonshot, while also directing USDA, Interior, HHS, and EPA to issue additional prize‑competition announcements or direct research programs for non‑chemical disease‑reduction methods. These incentives are intended to mobilize private‑sector innovation, leveraging commercial capabilities or cooperative agreements to achieve the reduction targets.

Operational and Policy Impact

The Order sets quantitative benchmarks of a 90 % reduction in mosquito populations and a 50 % reduction in tick populations by 2028 [1]. The record does not discuss how these benchmarks will influence agency resource allocation, contracting decisions, or budgeting over the six‑year horizon.

Implementation will require agencies to develop and apply non‑chemical, technology‑enabled tools on federal lands. The fact sheet notes that the campaign will focus on remediation of breeding grounds on federal property, but it does not specify that agencies must map and remediate breeding sites on **all** federal parcels within Washington, D.C. The record does not provide details on the extent of mapping or remediation required.

The regulatory framework for advanced control technologies will shape the legal landscape for future pest‑control products nationwide. Once established, the framework could serve as a template for other jurisdictions seeking to adopt non‑chemical, technology‑enabled methods, effectively extending the D.C. pilot model. However, the fact sheet does not detail the content of the framework, the approval process, or any cost‑sharing arrangements, leaving the precise financial burden on federal agencies and potential commercial partners undefined.

The labeling directive for alpha‑galactose products introduces a consumer‑health dimension that could affect food manufacturers, pharmaceutical companies, and retailers. By exploring labeling similar to existing allergy warnings, the Order may create new compliance requirements for products containing significant alpha‑galactose, though the fact sheet does not specify timelines or enforcement mechanisms. If USDA and HHS move forward with formal guidance, industry‑wide label revisions could follow.

Overall, the Order integrates vector control, biomedical research, and consumer‑product labeling into a single executive action. While the document offers clear quantitative goals and agency responsibilities, many operational specifics—such as funding levels, contracting procedures, and inter‑agency coordination mechanisms—remain unaddressed. Stakeholders will need to monitor agency releases for further detail.

What to Watch

- **Progress toward reduction targets**: Whether mosquito populations are reduced by 90 % and tick populations by 50 % in Washington, D.C. by 2028 [1]

- **Regulatory framework development**: Publication of the EPA‑led framework for advanced tick and mosquito control technologies (no deadline specified) [1]

- **Prize competition announcements**: Timing and scope of prize competitions and research program funding by HHS, USDA, Interior, and EPA [1]

- **Alpha‑galactose labeling guidance**: Development of labeling guidance for food and drug products containing significant alpha‑galactose by USDA and HHS (no date set) [1]